The Prevnar 20 approval comes a few weeks ahead of an FDA decision on Merck's V114, which was granted a priority review by the regulator in January for the prevention of IPD in adults.

The randomised, double-blind, active-controlled Phase II study compared the vaccine’s tolerability, immunogenicity, and safety against Prevnar 20 (PCV20) in healthy infants. In Stage 1 ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

Our respiratory vaccines, Abrysvo and Prevnar 20, also are key products in our commercial portfolio. We have achieved a market leadership position for the season in shipped doses for Abrysvo with ...

It had a safety profile similar to Pfizer's market-leading Prevnar 20, which targets 20 common serotypes, but at the highest dose tested generated stronger protection on 18 out of 20 of them ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...

Benjamin Hill travels the nation collecting stories about what makes Minor League Baseball unique. This excerpt from his ...

Uvax Bio, LLC, (“Uvax” or “the Company”) a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP ® protein-based vaccines, ...

The randomised, double-blind, active-controlled Phase II study compared the vaccine’s tolerability, immunogenicity, and safety against Prevnar 20 (PCV20) in healthy infants. Tick here to opt out of ...

Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino ...